94088-45-6

Basic information

• Product Name: 6-benzyloxy-2-fluorobenzonitrile
• Synonyms: 6-benzyloxy-2-fluorobenzonitrile;2-Fluoro-6-(phenylmethoxy)benzonitrile;Benzonitrile, 2-fluoro-6-(phenylMethoxy)-;2-Fluoro-6-benzyloxybenzonitrile
• CAS NO: 94088-45-6
• Molecular Formula: C14H10FNO
• Molecular Weight: 227.2337032
• EINECS: 302-045-4
• Mol File: 94088-45-6.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 359.441 °C at 760 mmHg
• Flash Point: 171.184 °C
• Appearance: /
• Density: 1.211 g/cm³
• Vapor Pressure: 2.38E-05mmHg at 25°C
• Refractive Index: 1.58
• CAS DataBase Reference: 6-benzyloxy-2-fluorobenzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 6-benzyloxy-2-fluorobenzonitrile(94088-45-6)
• EPA Substance Registry System: 6-benzyloxy-2-fluorobenzonitrile(94088-45-6)

Safety Data

• Hazard Codes: T,Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 94088-45-6(Hazardous Substances Data)

Usage

General Description

6-Benzyloxy-2-fluorobenzonitrile is a chemical compound that is often used in the field of organic synthesis. As evident from its name, this substance has a benzyloxy group (an oxygen atom bonded with a benzyl group) and a fluoro group (a molecule of fluoride) attached to a benzonitrile structure (a benzene ring attached with a nitrile group). It's known for its particular reactivity, particularly in facilitating the construction of aryl-aryl bonds. Notably, it can act as a very effective cross-coupling partner in Suzuki-Miyaura reactions. Due to its usefulness and versatility, it's frequently employed in the pharmaceutical industry and in the development or synthesis of various organic materials.

InChI:InChI=1/C14H10FNO/c15-13-7-4-8-14(12(13)9-16)17-10-11-5-2-1-3-6-11/h1-8H,10H2

Upstream product

• 1897-52-5 2,6 difluorobenzonitrile 
• 100-51-6 benzyl alcohol 
• 100-39-0 benzyl bromide 
• 140675-43-0 2-Fluoro-6-hydroxybenzonitrile 

Downstream Products

• 123241-95-2 5-(benzyloxy)quinazoline-2,4-diamine 

Relevant articles and documents

ALKOXYBENZO-FIVE-MEMBERED (SIX-MEMBERED) HETEROCYCLIC AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF

The invention relates to alkoxybenzeno five- or six-member heterocyclic amines compounds as scheme I , in which the R1, R2 and R3 are consistent with the detailed description in the patent claim. The compounds can act as selective sphingomyelin synthase 2 (SMS2) inhibitors to treat diseases caused by abnormal increasing of sphingomyelin (SM). This invention also includes compounds as scheme I , including pharmaceutically acceptable salts, pharmaceutical compositions as the active ingredients, and their application in drugs which can prevent and cure diseases caused by abnormal increasing of SM. These diseases caused by abnormal increasing of SM include atherosclerosis, type II diabetes, fatty liver, obesity, metabolic syndromes, enteritis and other inflammatory diseases.

Discovery of 4-Benzyloxybenzo[ d]isoxazole-3-amine Derivatives as Highly Selective and Orally Efficacious Human Sphingomyelin Synthase 2 Inhibitors that Reduce Chronic Inflammation in db/ db Mice

Sphingomyelin synthase 2 (SMS2) is a promising therapeutic target for several chronic inflammation-associated diseases, including atherosclerosis, fatty liver, and insulin resistance. Herein, we report the identification of 4-benzyloxybenzo[d]isoxazole-3-amine derivatives as potent and highly selective SMS2 inhibitors through a conformational restriction strategy. After systematic structural modifications, several compounds with high selectivity and good potency in vitro were selected for further evaluation. Compound 15w demonstrated good pharmacokinetics (oral bioavailability, F = 56%) in vivo and has an inhibitory potency against sphingomyelin synthase activity when Institute of Cancer Research mice are provided with an oral dose of this compound. In addition, compound 15w attenuated chronic inflammation significantly in db/db mice after oral dosing for 6 weeks.

USE OF A QUINAZOLINE COMPOUND IN PREPARING A MEDICAMENT AGAINST FLAVIVIRIDAE VIRUS

Disclosed is a use of a quinazoline compound of Formula I having 2,4-diaminoquinazoline as a parent nucleus in preparation of a medicament for treating diseases caused by flaviviridae infection, especially a use in combating Hepatitis C virus infection and Dengue fever virus infection.